Eli-Lilly has launched India’s first disease-modifying Alzheimer’s drug, donenemab, under the brand name Lormalzi. Approved by the CDSCO in 2025, the treatment aims to slow cognitive decline in early-stage patients, though high costs and healthcare limitations may affect accessibility.
